Chromium Supplementation Reduces Resting Heart Rate in Patients with Metabolic Syndrome and Impaired Glucose Tolerance

Biol Trace Elem Res. 2018 Jun;183(2):192-199. doi: 10.1007/s12011-017-1128-6. Epub 2017 Aug 30.


Chromium (Cr) is considered as an important mineral, involved in biochemical reactions in human metabolic pathways. Organically bound Cr supplementation has been suggested to improve glycemia especially in patients with type 2 diabetes mellitus, but there are conflicting reports on efficacy. Effect of Cr is not clear in prediabetes status. Seventy patients with metabolic syndrome and impaired glucose tolerance (IGT), who are observed and treated in the Center of Preventive Cardiology of the University Hospital in Pilsen, were included in the prospective, randomized, double-blind, and placebo-controlled clinical study. Effect of Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening) on glucose, lipid metabolism, fat tissue hormones, oxidative stress, and DNA damage markers was analyzed. There were no significant changes in glucose and lipid parameters, oxidative stress, or other laboratory markers. Only resting heart rate was significantly reduced in patients treated by Cr yeast, reflecting reduced sympathetic activity. This could represent an important cardiovascular risk reduction in patients with high cardiometabolic risk.

Keywords: Chromium yeast; Impaired glucose tolerance; Metabolic syndrome.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Chromium / administration & dosage
  • Chromium / therapeutic use*
  • DNA Damage / drug effects
  • Double-Blind Method
  • Glucose Intolerance / drug therapy*
  • Glucose Intolerance / physiopathology*
  • Heart Rate / drug effects
  • Humans
  • Lipid Metabolism / drug effects
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / physiopathology*
  • Oxidative Stress / drug effects
  • Prospective Studies


  • Chromium